Trials / Completed

CompletedNCT01879007

Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 16 (actual)

Sponsor: LG Life Sciences · Industry
Sex: Male
Age: 19 Years – 45 Years
Healthy volunteers: Accepted

Summary

This study seeks to compare the pharmacokinetic characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) with those of Factive 320mg Tablet Formulation (Gemifloxacin 320mg) and to explore possibility of clinical use of the IV formulation.

Conditions

Infectious Diseases

Interventions

Type	Name	Description
DRUG	Factive® Tab / Factive IV

Timeline

Start date: 2006-01-01
Primary completion: 2006-03-01
First posted: 2013-06-17
Last updated: 2013-06-17

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01879007. Inclusion in this directory is not an endorsement.